8-K filed January 10, 2025, 6:59 PM ET ticker NTLA CIK 0001652130

other material confidence high sentiment neutral materiality 0.80

Intellia Therapeutics, Inc. (NTLA): restructuring charge — Intellia restructures to focus on NTLA-2002 and nex-z, cuts 27% headcount, extends cash runway to H1 2027

Intellia Therapeutics, Inc.

Preliminary cash, cash equivalents and investments of $862M as of Dec 31, 2024.
Strategic restructuring: prioritize NTLA-2002 and nex-z; discontinue NTLA-3001 and select research programs.
Net workforce reduction of approximately 27% in 2025; estimated $8M restructuring charges in Q1 2025.
Cash runway extended to first half of 2027.
CSO Laura Sepp-Lorenzino to retire Dec 31, 2025; Birgit Schultes promoted to EVP and CSO effective Jan 13, 2025.

item 2.02 item 2.05 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Laura Sepp-Lorenzino

Executive Vice President and Chief Scientific Officer

NTLA · Intellia Therapeutics, Inc.

Effective: 2025-12-31
Successor: Birgit Schultes
Filed: January 10, 2025, 6:59 PM ET

Laura Sepp-Lorenzino, Ph.D., the Company’s Executive Vice President and Chief Scientific Officer (“CSO”), will retire from the Company and that her anticipated retirement date is December 31, 2025.

Role change

Laura Sepp-Lorenzino

Special Advisor to the Chief Executive Officer

NTLA · Intellia Therapeutics, Inc.

Effective: 2025-01-13
Filed: January 10, 2025, 6:59 PM ET

effective January 13, 2025, Dr. Sepp-Lorenzino will become Special Advisor to the Chief Executive Officer of the Company.

Appointed

Birgit Schultes

Executive Vice President and Chief Scientific Officer

NTLA · Intellia Therapeutics, Inc.

Effective: 2025-01-13
Filed: January 10, 2025, 6:59 PM ET

Birgit Schultes, Ph.D. will become the Company’s Executive Vice President and CSO, effective as of January 13, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Laura Sepp-Lorenzino departed as Executive Vice President and Chief Scientific Officer at Intellia Therapeutics, Inc..

Action: will retire
Role: Executive Vice President and Chief Scientific Officer

Exact text from the filing

Laura Sepp-Lorenzino, Ph.D., the Company’s Executive Vice President and Chief Scientific Officer (“CSO”), will retire from the Company and that her anticipated retirement date is December 31, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Laura Sepp-Lorenzino changed role as Special Advisor to the Chief Executive Officer at Intellia Therapeutics, Inc..

Action: will become
Role: Special Advisor to the Chief Executive Officer

Exact text from the filing

effective January 13, 2025, Dr. Sepp-Lorenzino will become Special Advisor to the Chief Executive Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Birgit Schultes was appointed as Executive Vice President and Chief Scientific Officer at Intellia Therapeutics, Inc..

Action: will become
Role: Executive Vice President and Chief Scientific Officer

Exact text from the filing

Birgit Schultes, Ph.D. will become the Company’s Executive Vice President and CSO, effective as of January 13, 2025.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Intellia Therapeutics, Inc. announced a restructuring with charges of approximately $8 million (approximately 27%).

Type: restructuring
Charge: approximately $8 million
Headcount: approximately 27%

Exact text from the filing

On January 9, 2025, the Company announced the prioritization of its current and near-term clinical programs and a strategic restructuring to streamline its operations. These changes are expected to extend the Company’s cash runway into the first half of 2027. In connection with this portfolio prioritization and strategic restructuring, the Company expects to implement a net reduction of its employee headcount by approximately 27% over 2025. The Company estimates that it will incur charges of approximately $8 million for severance and other employee termination-related costs, primarily in the first quarter of 2025.

View on SEC.gov

Browse all restructurings & charges →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-004080

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.